Cellectis (CLLS) Reports Q2 Loss of EUR0.23/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Nasdaq futures lead Wall St gains as oil retreat eases inflation worries
- Oil prices set for weekly fall on easing fears over Saudi supply disruption
- The Fed is hiking. Why isn't UBS worried about stocks?
- Wall Street on Fed rate hike: 'As hawkish as it gets'
- RBC bullish on Kraft Heinz, sees return to growth in 2027
Cellectis Reports 2nd Quarter and First Half Year 2016 Financial Results
September 8, 2016 5:31 PM EDT- First patient dosed in phase 1 clinical trial for UCART19
- UCART 123 manufacturing ongoing
- Strong cash position of $300 million1 (270 million) as of June 30, 2016
- Revenues and other income of $20 million2 (18 million) in the 2nd quarter of 2016
- Adjusted income attributable to shareholders3 of $9 million2 (8 million) in the 2nd quarter of 2016
NEW YORK--(BUSINESS WIRE)-- Regulatory News:
Cellectis S.A. (Paris: ALCLS) (NASDAQ: CLLS) (Alternext: ALCLS - Nasdaq: CLLS), a... More
